Psych Congress September 1 - 2025 Supporting materials POSTER: Development of a Machine Learning Model Predicting Response to Aripiprazole Once-Monthly in Patients Diagnosed With Bipolar I Disorder POSTER: Real-world Impact of Transitioning from Oral or Once-monthly Injectable Aripiprazole to a 2-Month Ready-To-Use Aripiprazole Formulation on Adherence and Healthcare Utilization in US Adults Diagnosed with Schizophrenia POSTER: Real-World Healthcare Resource Utilization and Costs Among US Individuals Living with Schizophrenia Who Transitioned to Aripiprazole 2-Month Ready-To-Use Formulation POSTER: Real-World Healthcare Resource Utilization and Costs Among US Individuals Living with Bipolar-I Disorder Who Transitioned to Aripiprazole 2-Month Ready-To-Use Formulation POSTER: Effect of brexpiprazole in combination with sertraline on post-traumatic stress disorder symptom clusters: intrusion, avoidance, negative cognitions/mood and arousal/reactivity POSTER: Assessment of Efficacy Outcomes Based on Treatment Adherence to Rejoyn (CT-152), a Digital Therapeutic for Patients With Major Depressive Disorder, During the Mirai Trial POSTER: Evaluating Changes in Anxiety Symptoms With Rejoyn (CT-152) Among Participants With Major Depressive Disorder and Comorbid Anxiety POSTER: Development of a Machine Learning Model Predicting Response to Aripiprazole Once-Monthly in Patients Diagnosed With Schizophrenia POSTER: A Quantitative Survey-based Study of Patient Preferences for a Long-acting Injectable Antipsychotic Administered Once Every 2 Months for Schizophrenia POSTER: Efficacy of Aripiprazole Once-Monthly and Aripiprazole 2-Month Ready-To-Use on Insight in Schizophrenia: Post Hoc Analyses of Three Trials POSTER: Symptoms of Major Depressive Disorder That Potentially Benefit From the Digital Therapeutic CT-152 POSTER: Patient-reported symptom severity and functioning with brexpiprazole in combination with sertraline in adults with post-traumatic stress disorder POSTER: Efficacy of brexpiprazole in combination with sertraline on individual symptoms of post-traumatic stress disorder in adults POSTER: Efficacy of CT-152 for Major Depressive Disorder Using the Self-Reported 9-Item Patient Health Questionnaire in Participants With Baseline Anxiety Symptoms and/or Difficulty Sleeping POSTER: Responders and Participant-Reported Depressive Symptom Clusters That May Benefit From CT-152 Therapy for Major Depressive Disorder POSTER: Development of a Machine Learning Model Predicting Response to Aripiprazole Once-Monthly in Patients Diagnosed With Schizophrenia POSTER: Efficacy of Centanafadine on Conners 3 Content Scales in Adolescents With Attention-Deficit/Hyperactivity Disorder POSTER: Development of a Machine Learning Model Predicting Response to Aripiprazole Once-Monthly in Patients Diagnosed With Bipolar I Disorder POSTER: Efficacy of Centanafadine on Conners 3 Content Scales in Children With Attention-Deficit/Hyperactivity Disorder POSTER: Comparison of Caregiver Exit Survey With Efficacy Measures in the Treatment of Attention-Deficit/Hyperactivity Disorder With Centanafadine in a Pediatric Population POSTER: Clinically Meaningful, Caregiver-Rated Improvements in ADHD Symptoms Following 6 Weeks of Centanafadine Treatment in Pediatric Patients With ADHD POSTER: Impact of Centanafadine on Executive Functioning in Pediatric Patients With Attention-Deficit/ Hyperactivity Disorder: Analysis of Conners 3 and Exit Survey Responses POSTER: Impact of Intrinsic Factors on the Efficacy of Centanafadine in an Adult Population with Attention-Deficit/Hyperactivity Disorder
